Sarah Rusch

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

Damayanthi Devineni, Christopher R. Curtin, David Polidori et al. · The Journal of Clinical Pharmacology · 2013 · 211 citations

Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study

Marita Stevens, Sarah Rusch, John P. DeVincenzo et al. · The Journal of Infectious Diseases · 2018 · 81 citations

Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants

Damayanthi Devineni, Nicole Vaccaro, David Polidori et al. · Clinical Therapeutics · 2014 · 49 citations · Full text

Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor

Damayanthi Devineni, Christopher R. Curtin, Thomas Marbury et al. · Clinical Therapeutics · 2015 · 49 citations

Metabolic Syndrome, Renal Function, Hepatology +10

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial

Peter Stein, Jolene Kay Berg, Linda Morrow et al. · Metabolism · 2014 · 47 citations · Full text